Article
20 Jun 2025
Health Canada Proposes To Remove Phase III Trial Requirement From Biosimilar Approval Pathway
Alex Gloor
Popular Topics
Intellectual Property
Food, Drugs, Healthcare, Life Sciences
RANKINGS
This author falls within the Top 20% for their listed topics and industry categories. Based on Mondaq users readership, this author is ranked as VERY POPULAR in Canada
AUTHORS CONTENT
Article
13 Jan 2025
Canadian Patent Law: 2024 In Review
Article
04 Mar 2024
Federal Court Of Appeal Addresses Patentability Of Methods Of Medical Treatment In Canada
Article
23 Jan 2024
Canadian Patent Law: 2023 Year In Review
Article
01 May 2023
Ontario Superior Court Dismisses Claim For Section 8 Damages
Article
17 Jan 2023
Canadian Patent Law: 2022 Year In Review
Article
31 Oct 2022
Crocs Successfully Asserts Industrial Design, Awarded Infringer's Profits
Article
15 Jun 2022
Promise Me No Promises? The Five-year Anniversary Of The Supreme Court's AstraZeneca Decision
Article
03 Mar 2022
Canadian Patent Law: 2021 Year In Review
Article
30 Dec 2021
Amendments To The Patented Medicines Regulations Delayed Six Months, Until July 1, 2022
Article
08 Dec 2021
Patent Litigation Trends: The Future Of Biologics?
Article
06 May 2021
PMPRB Seeks Feedback On Guideline Monitoring And Evaluation Plan
Article
29 Apr 2021
Proposed Amendments To Listing Patents On Canada's Patent Register
Article
17 Mar 2021
Federal Court Of Appeal Dismisses Appeals Brought By Apotex In Respect Of Takeda's Canadian VYVANSE® Patent
Article
15 Mar 2021
Ontario Superior Court Of Justice Dismisses Statute Of Monopolies Action Via Summary Judgment
Article
03 Feb 2021
Second Medical Use Patents Part 2 - Verifying Validity
Article
25 Jan 2021
Second Medical Use Patent Series: Understanding Infringement And Enforcement (Video)
Article
15 Jan 2021
Canadian Patent Law: 2020 Year In Review
Article
04 Jan 2021
Amendments To The Patented Medicines Regulations Delayed By 6-months, Until July 1, 2021
Article
20 Apr 2020
Better Together – Federal Court Supports Broader Interpretation Of CSP Regulations Based Upon A Purposive Review Of CETA